TITLE

ANGIOTECH ANNOUNCES PSORIASIS GEL DETERMINED TO BE SAFE

PUB. DATE
October 2000
SOURCE
Worldwide Biotech;Oct2000, Vol. 12 Issue 10, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces the results of clinical trials made by Angiotech Pharmaceuticals Inc. on its Topical Paclitaxel Gel formulation for the treatment of psoriasis.
ACCESSION #
3635168

 

Related Articles

  • Efalizumab results hopeful. Guttman, Cheryl // Dermatology Times;Aug2001, Vol. 22 Issue 8, p1 

    Reports on the results of Phase III trial of efalizumab as treatment for moderate-to-severe psoriasis presented by physician Alice B. Gottlieb at the International Psoriasis Symposium. Convenience derived from using efalizumab; Percentage of patients who achieved a reduction of 75% or more in...

  • Alefacept efficacious therapy for long-lasting relief. Guttman, Cheryl // Dermatology Times;Aug2001, Vol. 22 Issue 8, p1 

    Reports on the initial results of Phase III trials of alefacept as treatment for moderate-to-severe psoriasis presented by physician Mark Lebwohl at the International Psoriasis Symposium. Details of the two randomized placebo-controlled trials; Data analyses of the IV and IM trials; Efficacy...

  • Psoriasis market anticipates new, effective biologic agents. Liebman, Milton // Medical Marketing & Media;Sep2002, Vol. 37 Issue 9, p24 

    Reports on the clinical testing for a class of biologic agents in the U.S. Elimination of psoriasis; Efficiency in blocking the over-activation of T cells; Duration of remission.

  • Efalizumab Efficiency. Guttman, Cheryl // Dermatology Times;Apr2003, Vol. 24 Issue 4, p31 

    Focuses on the Phase III clinical trial of efalizumab, a monoclonal antibody for the treatment of psoriasis in San Francisco, California. Details on patients' response to the treatment; Reduction in the symptoms; Confirmation on the safety and efficacy of the drug.

  • Redefining Efficacy in Chronic Plaque Psoriasis.  // Dermatology Times;Jul2003, Vol. 24 Issue 7, p68 

    Evaluates the efficacy of the Psoriasis Area Severity Index (PASI) in assessing the standards for measuring psoriasis severity and treatment response in clinical trials. Calculation of patient's PASI scores using a mathematical formula; Details on the clinical characteristics of erythema,...

  • Rapid Response Therapy/Efalizumab improves quality of life in moderate to severe psoriasis. Wilson, Fred // Dermatology Times;Mar2003, Vol. 24 Issue 3, p30 

    Reports on the efficacy of efalizumab in improving the quality of life of patients with moderate to severe psoriasis. Clinical trial for efalizumab; Reduction in chronic inflammation; Estimation of the psoriatic frequency and severity.

  • Rheumatoid Arthritis Drug Adalimumab Being Tested in Phase II Trial. Hilton, Lisette // Dermatology Times;Sep2003 Supplement 4, Vol. 24 Issue 9, pS26 

    Focuses on the launch of a multicenter, randomized placebo-controlled trial to assess the efficacy of adalimumab (Humira) for the treatment of psoriasis by researchers in Maywood, Illinois. Importance of tumor necrosis factor-alpha; Background information of adalimumab; Disadvantage of Humira.

  • Psoriasis drug reaches pivotal clinical stage. Guttman, Cheryl // Dermatology Times;Nov2000, Vol. 21 Issue 11, p1 

    Reports that alfacept (Amevive), a recombinant LFA-3/IgG[sub 1] human fusion protein, has advanced into pivotal premarketing clinical trials, according to Dr. Gerald G. Krueger. Investigation into a 7.5 mg/kg dose given once weekly by IV bolus injection or 10 or 15 mg IM injection for treatment...

  • Resetting the Research Agenda for Psoriasis. Chalmers, Robert JG; Griffiths, Christopher EM // Journal of Investigative Dermatology;May2003, Vol. 120 Issue 5, pix 

    Comments on the European Dermato-Epidemiology Network survey of randomized controlled trials (RCT) in psoriasis. Performance of the dermatology community; Efforts to evaluate treatments for psoriasis; Evaluation of RCT in psoriasis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics